Protective effect of Actinidia arguta in MPTP-induced Parkinson's disease model mice

Biochem Biophys Res Commun. 2021 May 28:555:154-159. doi: 10.1016/j.bbrc.2021.03.116. Epub 2021 Apr 2.

Abstract

Parkinson's disease (PD) is a neurodegenerative disease characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra. Oxidative stress-induced neuronal death has been identified as one of the major causes of nigrostriatal degeneration in PD. The fruit of Actinidia arguta (A. arguta), known as sarunashi in Japan, has been reported to show beneficial health effects such as antioxidant, anti-inflammatory, anti-mutagenic, and anticholinergic effects. In this study, we investigated the neuroprotective effects of A. arguta in 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP)-induced PD model mice. A. arguta juice was administered to 7-week-old C57BL/6J mice continuously for 10 days before the first MPTP injection. The degeneration of dopaminergic neurons in the substantia nigra was induced by MPTP (30 mg/kg, i. p.) once daily for five consecutive days. We found that the administration of A. arguta ameliorated MPTP-induced motor impairment and suppressed the MPTP-induced reductions of tyrosine hydroxylase-positive neurons and tyrosine hydroxylase protein expression in the substantia nigra. Our findings suggest that taking A. arguta could provide neuroprotection that delays or prevents the neurodegenerative process of PD.

Keywords: Actinidia arguta; Neuroprotection; Parkinson’s disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actinidia / chemistry*
  • Animals
  • Blotting, Western
  • Catalepsy / chemically induced
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / pathology
  • Fruit and Vegetable Juices
  • MPTP Poisoning / complications
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / pharmacology*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / etiology
  • Parkinson Disease, Secondary / drug therapy
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Neuroprotective Agents
  • Tyrosine 3-Monooxygenase